Zelinger, D.J.

patient abciximab treatment ce ratios ratio effect ce ratio analysis cost-effectiveness trial angina estimate uncertainty abciximab treatment point result survival probability study 1 year evaluation heart life-year epic study therapy group event effectiveness placebo decision measure difference ellipses subgroup analyses angioplasty revascularization problem number survivor event-free end points life expectancy angina group point estimates limit subgroup analysis american outcome journal increase point b syndrome example balance /iiia model time horizon center angina subgroup percutaneous transluminal efficacy measures figure abciximab bolus cost-effectiveness analyses efficacy netherland event-free survivor ischemic car b assumption question table decrease randomized expectancy horizon 7 e 3 health platelet